Ц.Алтантуяа
Loading...
Товч нэр
Ц.Алтантуяа
Бүтэн нэр
Цэвгээ Алтантуяа
Латин нэр
Tsevgee Altantuya
Албан тушаал
Багш
Харьяалал
Scopus Author ID
2 results
Now showing 1 - 2 of 2
- Some of the metrics are blocked by yourconsent settings
Item type:Publication, Newborn screening and biobanking for preventable genetic disorders in Mongolia: A developing country perspective(Elsevier BV, 2026-12); ; ; ; Newborn screening (NBS) is an important public health program, yet its implementation is highly uneven globally, with developing countries like Mongolia facing significant resource and infrastructure limitations that hinder early detection of preventable genetic disorders. Meanwhile, induced pluripotent stem cell (iPSC) technology, leveraged through biobanking, offers a powerful platform for disease modeling, drug discovery, and regenerative medicine, though its advanced applications are primarily concentrated in wealthier nations. We review the current status of NBS in Mongolia and argue for linking an expanded NBS program to an iPSC biobank. This link would improve diagnosis, create a foundation for Mongolian precision medicine, and strengthen local research capacity. We recognize the practical and ethical hurdles-funding, staffing, and data governance-and outline phased rollout, targeted training, and international partnerships as realistic next steps. Taken together, this approach could prevent avoidable disability in Mongolia while gradually building homegrown capability in genetic healthcare. - Some of the metrics are blocked by yourconsent settings
Item type:Publication, First Experiences with Newborn Screening for Congenital Hypothyroidism in Ulaanbaatar, Mongolia(MDPI AG, 2021-06); ; ;Munkhchuluun, Tsolmon ;Khurelbaatar, NaranchimegNansal, GerelmaaCongenital hypothyroidism (CH) is among the most common conditions leading to intellectual disability, which can be prevented by early detection through newborn screening (NBS). In Mongolia, a regional screening program for CH was launched in 2000, which was supported by the International Atomic Energy Agency (IAEA) for the Asia Pacific Region. In our present study, a total of 23,002 newborns from nine districts in Ulaanbaatar were screened between 2012 and 2020, by the measurement of the thyroid-stimulating hormone (TSH) from dried blood spots, sampled 24 to 72 h after birth. The level of TSH was measured by the DELFIA assay. The overall CH prevalence confirmed at birth was 1/2091. The female-to-male ratio for CH cases was 1.8:1. The majority of patients were asymptomatic (72.7% of CH cases); umbilical hernia and cold or mottled skin were reported symptoms in patients with CH (27.3%). Thyroid dysgenesis (hypoplasia and agenesis) was the most common etiology, with a total of nine cases (81.8%) out of the eleven patients. The lapse between the birth date and the initiation of L-thyroxine treatment in CH-positive children was lower than 15 days in 63.64% of cases or 15 to 30 days in 36.36% of children. Further research is required to expand the screening coverage for CH in Mongolia.Scopus© Citations 5
